ライフサイエンスコーパス: receptor subtype

1 ation is primarily through the adenosine A2a receptor subtype.

2 ols to evaluate the functional roles of this receptor subtype.

3 thought to be devoid of activity at the S1P2 receptor subtype.

4 (Delta-41 +/- 7%) via activation of the V1a receptor subtype.

5 oscillations in both species via the 5-HT1A receptor subtype.

6 amine binding to the allosteric site at this receptor subtype.

7 hypotheses for the improved affinity to this receptor subtype.

8 his arises from activation of the AT1 Ang II receptor subtype.

9 predicted by independent expression of each receptor subtype.

10 hypotheses for the improved affinity to this receptor subtype.

11 e selectivity and/or affinity for a specific receptor subtype.

12 and pathological responses of the individual receptor subtypes.

13 lectivity over the related 5-HT2A and 5-HT2B receptor subtypes.

14 ionship and defining them as pharmacological receptor subtypes.

15 eric site is in the micromolar range for all receptor subtypes.

16 ns on different native and recombinant GABAA receptor subtypes.

17 unlike other FGF peptides, activates all FGF receptor subtypes.

18 tochastic activation of different macrophage receptor subtypes.

19 lining the intramembranous pocket in the two receptor subtypes.

20 diate antinociception through the A1 and A2A receptor subtypes.

21 set of approximately 400 different olfactory receptor subtypes.

22 llosteric ligands now available for all mGlu receptor subtypes.

23 binding pocket at any of the five muscarinic receptor subtypes.

24 iological actions of NPY are assigned to NPY receptor subtypes.

25 tly stimulating internalization of the three receptor subtypes.

26 have little or no effect on other muscarinic receptor subtypes.

27 s highly potent antagonists of GluA2-lacking receptor subtypes.

28 nt new chemotypes for the alpha7 and alpha3* receptor subtypes.

29 y due to nonspecific actions on various 5-HT receptor subtypes.

30 ights into the selectivity between melatonin receptor subtypes.

31 nes displayed the lowest K(i) values on both receptor subtypes.

32 ve, Her2-overexpressing, and triple negative receptor subtypes.

33 ney 293 cells stably expressing different EP receptor subtypes.

34 has sought to identify selective ligands for receptor subtypes.

35 d mutation data across ligand chemotypes and receptor subtypes.

36 d expression levels across all breast cancer receptor subtypes.

37 ility to distinguish between closely related receptor subtypes.

38 with a differential activation of glutamate receptor subtypes.

39 nces in agonist efficacy at recombinant NMDA receptor subtypes.

40 electivity for either the kappa or the delta receptors subtypes.

41 tress through corticotropin-releasing factor receptor subtype 1 (CRF(1)) expressed on MCs.

42 ype 4 (M4) to oppose cAMP-dependent dopamine receptor subtype 1 (D1) signaling in presynaptic termina

43 tdTomato driven by the promoter for dopamine receptor subtype 1 (D1).

44 Ryanodine receptor subtype 1 (RyR1) supports relaxation of arteria

45 that corresponded with the engagement of S1P receptor subtype 1 (S1PR(1))- dependent neuroinflammator

46 athic pain by selectively activating the S1P receptor subtype 1 (S1PR1) in astrocytes.

47 the preparation of muscarinic acetylcholine receptor subtype 1 positive allosteric modulators.

48 d the prostaglandin E receptor, prostanoid E receptor subtype 1, are involved in seizure-mediated P-g

49 owing selectivity with respect to the orexin receptor subtype 1.

50 s the role of corticotropin releasing factor receptor subtypes 1 and 2 (CRFR1, CRFR2) within the vent

51 oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lympho

52 selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity.

53 ate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity.

54 nd functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs).

55 llosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu1-5,7) highlighting key

56 acid (1b), for cloned homomeric kainic acid receptors subtype 1 (GluK1) was attained (Ki = 4 muM).

57 ductance via the growth hormone secretagogue receptor subtype 1a-Galphai -PI3K-Erk1/2-KATP pathway.

58 bution and transcript abundance of melatonin receptor subtype 1B (mel1b), shown to be important for v

59 ross-linking strategy to map the cannabinoid receptor subtype 2 (CB2)-Galphai interface and then used

60 The activation of cannabinoid receptor subtype 2 (CB2R) prevents acinar cell pathogene

61 The cannabinoid receptor subtype 2 (CB2R) represents an interesting and

62 d the role of corticotropin-releasing factor receptor subtype 2 (CRF(2)) as a modulator of stress-ind

63 y mouse microglia that lack prostaglandin E2 receptor subtype 2 (EP2) show decreased innate immune-me

64 and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB(2)R) agonist and investigated th

65 n 12.6 (FKBP12.6), is a subunit of ryanodine receptor subtype 2 (RyR2) macromolecular complex, which

66 and survival via the sphingosine 1-phosphate receptor subtype 2 (S1P2) followed by an inhibition of A

67 vitro and in vivo evidence that somatostatin receptor subtype 2 (sst2) antagonists are better tools t

68 Somatostatin receptor subtype 2 (sstr2) is a G-protein-coupled recept

69 with picomolar affinity for the somatostatin receptor subtype 2 (SSTR2) upregulated in some pancreati

70 o a G protein-coupled receptor, somatostatin receptor subtype 2 (SSTR2), in pituitary cells.

71 n for drugs that upregulate the somatostatin receptor subtype 2 (sstr2).

72 ecently solved X-ray structure of the orexin receptor subtype 2 in computational docking calculations

73 The somatostatin receptor subtype 2 is expressed on macrophages, an abund

74 AMBF3-TATE bound the somatostatin receptor subtype 2 with high affinity (inhibition consta

75 ctedly high binding affinity to somatostatin receptor subtype 2, and showed excellent pharmacokinetic

76 Visualization of somatostatin receptor subtype 2, for oncologic purposes, is frequentl

77 d (64)Cu and tested in vitro in somatostatin receptor subtype 2-overexpressing HEK-293 cells to asses

78 cells expressing high levels of somatostatin receptor subtype 2.

79 highest affinity yet found for somatostatin receptor subtype 2.

80 ective antagonists of metabotropic glutamate receptor subtypes 2 (mGlu(2)) and 3 (mGlu(3)) exert rapi

81 the role of group II metabotropic glutamate receptor subtypes 2 (mGlu(2)) and 3 (mGlu(3)) in the ant

82 The serotonin receptor subtypes 2 comprise 5-HT2A, 5-HT2B, and 5-HT2C,

83 a-DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5 (sst2,3,5).

84 otid plaques were retrieved for somatostatin receptor subtype-2 (sst2) immunohistochemical staining.

85 d DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET tracer, for imagin

86 (Cmpd-1), a novel A2AR/N-methyl d-aspartate receptor subtype 2B (NR2B) dual antagonist and potential

87 The somatostatin receptor subtype 3 (Sstr3) is selectively targeted to pr

88 activated with U46619 and prostaglandin E(2) receptor subtype 3 activated with iloprost showed a simi

89 with PV toward the muscarinic acetylcholine receptor subtypes 3, 4, and 5 as well as thyroid peroxid

90 or (GPCR) agonists, stimulating the bombesin receptor subtype-3 (BB3) GPCR.

91 This effect was mediated through PGE2 receptor subtype 4 (EP4) and an increase in intracellula

92 culata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M4) to oppose cAMP-dependent dopamin

93 re, we identified the metabotropic glutamate receptor subtype 4 (mGluR4) as a promising pharmacologic

94 f the PTGER4 gene (encoding prostaglandin E2 receptor subtype 4; all P < 5 x 10(-5)).

95 Metabotropic glutamate receptor subtype 5 (mGlu5) activators have emerged as a

96 ric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5) have exciting potential as th

97 The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely associated signa

98 ed that expression of metabotropic glutamate receptor subtype 5 (mGluR5) in the VMH is regulated by c

99 The metabotropic glutamatergic receptor subtype 5 (mGluR5) may represent a promising th

100 ave been proposed and metabotropic glutamate receptor subtype 5 (mGluR5) represents one such candidat

101 c radioligand for the metabotropic glutamate receptor subtype 5 (mGluR5).

102 ketamine on brain metabotropic glutamatergic receptor subtype 5 with a high-affinity positron emissio

103 The serotonin receptor subtype 5-HT(1A) was one of the first serotonin

104 to advance the novel concept that serotonin receptor subtype 5-HT2C contributes critically to the im

105 the basolateral nucleus (BLA) and serotonin receptor subtype 5-HT2CR in the BLA, but not CeA, has be

106 modulator of the metabotropic glutamatergic receptor subtype 5.

107 tivation mechanism of metabotropic glutamate receptor subtype 5.

108 n part, to changes in metabotropic glutamate receptors-subtype 5 (mGluR5) in the nucleus accumbens, a

109 The metabotropic glutamate receptor subtype 7 (mGlu7) is an important presynaptic r

110 The purinergic receptor subtype 7 (P2X7R) represents a novel molecular

111 Stimulation of the adenosine receptor subtype A2B increases the gap junction coupling

112 Acting at a single metabotropic receptor subtype, ACh exerts two opposing actions in cor

113 The crystal structures of the two receptor subtypes, ADIPOR1 and ADIPOR2, show a similar o

114 cation and recognition, suggesting that this receptor subtype affects consolidation and/or retrieval

115 The effects depend on receptor subtypes, affinity, concentration level, and th

116 uate the impact of the A2A and A2B adenosine receptor subtype agonist 2-phenylaminoadenosine (2-PAA)

117 nsfected with cDNAs encoding three requisite receptor subtypes: alpha7-nAChR, alpha4beta2-nAChR, and

118 Triple transfections of the dopamine receptor subtype and Gbeta and Ggamma subunits, each lab

119 yl-d-aspartate receptor (NMDAR), a glutamate receptor subtype and is involved in NMDAR-mediated neuro

120 Collectively, our findings show that D1 receptor subtype and related signaling in mPFC excitator

121 tory and antinociceptive target as both this receptor subtype and the pathways forming PGE2 are highl

122 (2A)AR, selectivity over all other adenosine receptor subtypes and allowed clear visualization of spe

123 Expressed adenosine receptor subtypes and connexin (Cx) isoforms were identi

124 teractions are seen for very closely related receptor subtypes and for varying drugs at a given bindi

125 s also emphasize the importance of 5-HT2A/1A receptor subtypes and the Asp system in the control of s

126 Distinct effects are dependent on receptor subtypes and their differential expression.

127 he dynamic interactions between the dopamine receptor subtypes and their G-proteins using two-color f

128 y difficult because of the diversity of skin receptor subtypes and their location within the dermis a

129 o either greater sequence divergence between receptor subtypes and/or subtype-selective cooperativity

130 ne (NECA) (10 muM; agonist for all adenosine receptor subtypes) and CGS21680 (10 muM; selective A2A a

131 role for gliotransmission and the sites, P2 receptor subtype, and signalling mechanisms via which AT

132 alue of 233 nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteri

133 sion levels of different extrasynaptic GABAA receptor subtypes, and on the ambient GABA levels.

134 affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie

135 distribution and the signaling mechanisms of receptor subtypes, and the dynamics of ACh hydrolysis.

136 ript focuses on SCI, these two innate immune receptor subtypes are also involved in developmental pro

137 ion are likely complicated, because multiple receptor subtypes are distributed throughout the olfacto

138 Multiple 5-HT receptor subtypes are expressed in the CA3 region of the

139 The present study points to these receptor subtypes as potential targets for the symptomat

140 ion appeared to be mediated via the RAR-beta receptor subtype, as ATRA remarkably induced RAR-beta mR

141 ctive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (enc

142 show that mutation in the alpha2 -adrenergic receptor subtype B (alpha2B -AR) is associated with ADCM

143 n is regulated by tropomyosin-related kinase receptor subtype B (TrkB) signaling in various neuronal

144 ferentiate between subpopulations of a given receptor subtype based on the receptor's dimerization st

145 in shaping emotional behavior; however, the receptor subtypes/brain regions through which this occur

146 were not only dependent upon the particular receptor subtype but also whether it was a pyramidal cel

147 dimer interfaces of ORs across the different receptor subtypes, but also important differences in the

148 fication of AMPA, kainate and NMDA glutamate receptor subtypes by Watkins and colleagues underlies mu

149 ific modulatory effects, we investigated the receptor subtypes, cell types and cellular mechanisms en

150 framework for the interpretation of observed receptor subtype combinations and possible assembly path

151 -5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor subtypes, confirmed also by an unusual binding

152 ted clinical efficacy as multiple Gq-coupled receptor subtypes contribute to these pathologies.

153 x (PFC) glutamate transmission; however, the receptor subtype contributions and underlying mechanisms

154 a(2+) signaling pathway linked to the VEGFR2 receptor subtype, controlling the critical angiogenic re

155 Thus, through distinct receptor subtypes coupled with different K(+) channels,

156 endogenous peptide urocortin1 (Ucn1) and two receptor subtypes, CRF-R1 and CRF-R2, in primary human a

157 Although CRF is known to activate two receptor subtypes, CRF1 and CRF2, attempts to delineate

158 The five dopamine receptor subtypes (D(1-5)) are activated by the endogeno

159 ated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB1.

160 tty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R).

161 owed preferences for particular melanocortin receptor subtypes depending on the linker that connected

162 g how structural differences among glutamate receptor subtypes determine their distinct functional pr

163 s and provides insights into how cannabinoid receptor subtypes diversify the roles of cannabinoids in

164 the major source of 5-HT, and expresses 5-HT receptor subtypes (e.g., 5-HT2C and 5-HT1A) critically l

165 The melanocortin system consists of five receptor subtypes, endogenous agonists, and naturally oc

166 mixed effects relate to 4 E-prostanoid (EP) receptor subtypes (EP1, 2, 3 and 4) expressed at differe

167 clinically relevant drugs target all GABA(A) receptor subtypes equally.

168 1) analyze the specificity of the histamine receptor subtypes for different heterotrimeric G-protein

169 ssible the selective blockade of vasopressin receptor subtypes for therapeutic purposes.

170 The alpha3beta4 nicotinic receptor subtype forms the principal relay between the c

171 f KOR, but not of the delta or the mu opioid receptor subtypes, fully blocked CR-induced hypothermia

172 form functional heteromers with the galanin receptor subtype Gal1 (Gal1R), which modulate the activi

173 tive heteromerization of MOR and the galanin receptor subtype Gal1 (Gal1R).

174 isruption of single muscarinic acetylcholine receptor subtype genes (M(1) to M(5)) and wild-type cont

175 ts unique pharmacological profile among NMDA receptor subtypes (GluN1/2A-D), in which DCS is a supera

176 GnRH receptor subtypes GnRHR1 and GnRHR2 were expressed in ch

177 ts on cholangiocytes by interaction with the receptor subtype (GnRHR1) expressed by cholangiocytes an

178 The four histamine receptor subtypes (H1R, H2R, H3R, and H4R) respond to th

179 This receptor subtype has long been object of intense researc

180 harmacological differences between these two receptor subtypes have been described in heterologous ex

181 Although three TA receptor subtypes have been identified (TAR1-3), specifi

182 In particular, the M1 and M4 receptor subtypes have emerged as attractive drug target

183 3) and worst when they expressed none of the receptors (subtype HR0).

184 ere best when tumors expressed all 3 hormone receptors (subtype HR3) and worst when they expressed no

185 of Fgf2 KO mice, suggesting a role for other receptor subtypes (i.e., FGFR5).

186 Compounds that can act on GABAA receptor subtype in a selective manner, without the side

187 ce, here we identified a role of dopamine D1 receptor subtype in mPFC excitatory neurons in suppressi

188 stress (R-SDS) reduces the expression of D1 receptor subtype in mPFC of mice susceptible to R-SDS.

189 However, isolating specific receptor subtype in recombinant systems can be problemat

190 opening the possibility of drugs targeting a receptor subtype in specific brain regions.

191 atter thickness and BPnd for either dopamine receptor subtype in the control group.

192 ceptor (GPCR) and the predominant adrenergic receptor subtype in the heart, where it mediates cardiac

193 Knockdown of D1 receptor subtype in whole neuronal populations or excita

194 Similarly, AT-1001 desensitized both receptor subtypes in a concentration-dependent manner, b

195 modulatory potential of multiple adrenergic receptor subtypes in a single IC cell, we measured co-ex

196 dual differences in the activity of specific receptor subtypes in hotspot processes proposed by the G

197 Cooperativity of E-prostanoid receptor subtypes in regulating signaling and growth inh

198 , and the relative contribution of glutamate receptor subtypes in the CN were significantly altered.

199 et functional synaptic localization of these receptor subtypes in the dorsal horn has not been fully

200 CRF acts on both CRF1 and CRF2 receptor subtypes in the DRN that exert opposing inhibit

201 trated the involvement of dopamine D4 and D2 receptor subtypes in the effects of pramipexole.

202 PA) receptors are two major, closely related receptor subtypes in the glutamate ion channel family.

203 thyl-4-isoxazole propionic acid) and kainate receptor subtypes in their major functional states and a

204 uits affected by this system and the precise receptor subtypes involved in this modulation have not b

205 The P2X(7) receptor subtype is a pharmacological target because of

206 The most frequent GABA(A) receptor subtype is composed of two alpha-, two beta-, a

207 Identifying which receptor subtype is involved could facilitate treatment

208 This GABAA receptor subtype is thought to mediate sedation.

209 e other three benzodiazepine-sensitive GABAA receptor subtypes, is self-administered, and that the al

210 For some receptor subtypes it has been difficult to separate ther

211 These include: identification of the primary receptor subtype; its location on endothelial (EC) or va

212 determine contributions of the three D2-like receptor subtypes, knockout (KO) mice completely lacking

213 othesis that the lack of a single muscarinic receptor subtype leads to age-dependent neuron reduction

214 azine, already identified as selective GABAA receptor subtype ligands endowed with anxiolytic-like an

215 Continuing our research on GABAA receptor subtype ligands, here is reported the synthesis

216 d rapidly reversible optical control of NMDA receptor subtypes, LiGluNs should help unravel the contr

217 ose dependently acting on distinct mu-opioid receptor subtypes located at different levels of the neu

218 vates erythropoiesis by activating the LPA 3 receptor subtype (LPA3) under erythropoietin (EPO) induc

219 -LSN3172176 for the muscarinic acetylcholine receptor subtype M1.

220 There are five muscarinic receptor subtypes (M1R to M5R), which, despite sharing a

221 We found that the muscarinic acetylcholine receptor subtype M3 (M3R) interacted directly with NOSTR

222 olinergic interneurons (ChIs) and muscarinic receptor subtypes (mAChRs) in the occurrence of a wide r

223 Thus, both receptor subtypes may contribute to methamphetamine-indu

224 6beta2* nAChRs and that antagonists of these receptor subtypes may exhibit therapeutic potential.

225 While the NAc expresses various HA receptor subtypes, mechanisms by which HA modulates NAc

226 icate that the D2R is the primary DA D2-like receptor subtype mediating the reinforcing effectiveness

227 Here we tested the hypothesis that the key receptor subtype mediating this effect is the D5 recepto

228 t that a breakdown of metabotropic glutamate receptor subtype mGluR5 and endocannabinoid signaling in

229 wever, it is unclear whether D2, D3, or both receptor subtypes modulate precise signals of feedback a

230 at also includes mu, delta, and kappa opioid receptor subtypes (MOR, DOR, and KOR, respectively).

231 ligands binding to the three classic opioid receptor subtypes, mu, kappa and delta, have high affini

232 OX2 receptors; a selective inhibitor of this receptor subtype, N-ethyl-2-[(6-methoxy-3-pyridinyl)[(2-

233 isruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic si

234 of the M1 receptor dimer population, but the receptor subtype non-selective antagonists atropine and

235 studies neither isolated a role of dopamine receptor subtype nor identified the site of its action i

236 th clinical outcomes of p53 and ER (estrogen receptor) subtypes of breast cancer, while also predicti

237 d PKC selectively phosphorylates the Robo3.1 receptor subtype on serine 1330.

238 Of the eight metabotropic glutamate (mGlu) receptor subtypes, only mGlu7 is expressed presynaptical

239 t therapeutics targeting a specific estrogen receptor subtype or its downstream signaling would likel

240 type 5-HT(1A) was one of the first serotonin receptor subtypes pharmacologically characterized.

241 pes of mPFC neurons express several dopamine receptor subtypes, previous studies neither isolated a r

242 d parallels the expression pattern of the Y1 receptor subtype previously described by our group, as i

243 ishing the specific properties of individual receptor subtypes remains a major goal in the field of n

244 criminating between the D(2), D(3), and D(4) receptor subtypes remains a significant challenge.

245 The pharmacological activation of LPA receptor subtypes represent a novel strategies for augme

246 ties for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively.

247 tenuation were mediated by CRF-R1 and CRF-R2 receptor subtypes, respectively, localized to presynapti

248 study attempted to identify the adiponectin receptor subtype responsible for adiponectin's vascular

249 However, the known repertoire of P2 receptor subtypes responsible for the proinflammatory ef

250 models of psychosis, although the particular receptor subtype(s) responsible for such activity was un

251 thylated analogues of the NMDA and AMPA iGlu receptor subtype selective antagonists ArgTX-93 and ArgT

252 Using novel mGlu receptor subtype-selective allosteric modulators along w

253 P2X receptor subtype-selective antagonists are promising can

254 lators are an attractive approach to achieve receptor subtype-selective targeting of G protein-couple

255 ith new physical properties, chemotypes, and receptor subtype selectivities.

256 te to a molecular understanding of melatonin receptor subtype selectivity and ligand access modes, wh

257 Here, we examine the GABAA receptor subtype selectivity of the weak partial agonist

258 tentiation of natural signaling, and that of receptor subtype selectivity.

259 bonds (cis-trans) plays an important role in receptor subtype selectivity.

260 at the two uridine diphosphate-activated P2Y receptor subtypes showed high CD73 selectivity, especial

261 ructions of On-Off DSGCs showed a GABAergic, receptor subtype-specific input field for generating dir

262 s.Hypothesizing that 5-HT may have cell- and receptor subtype-specific modulatory effects, we investi

263 The effects are determined by receptor subtype specificity, concentration level, and t

264 macrine cells and M1 ipRGCs express the SRIF receptor subtypes sst(2A) and sst4 respectively.

265 nctionally interchangeable and that multiple receptor subtypes subserving inhibition may offer divers

266 Moreover, the similar contribution of both receptor subtypes suggests the importance of a relative

267 >55 nM were found for all other human-cloned receptor subtypes tested.

268 educed agonist activity across all nicotinic receptor subtypes tested.

269 s of ethanol inhibit activity of a nicotinic receptor subtype that is expressed in brain areas associ

270 rties of the triheteromeric GluN1/2B/2D NMDA receptor subtype that is expressed in distinct neuronal

271 tulated that activation of the specific mGlu receptor subtype that mediates this response could inhib

272 pi, theta, rho1-3) can give rise to multiple receptor subtypes that are the site of action of many cl

273 e both biased agonism and the many mu opioid receptor subtypes that have been cloned.

274 There are four adenosine receptor subtypes that induce different signaling cascad

275 e stability and synaptic accumulation of the receptor subtypes that mediate these distinct forms of i

276 e hippocampus, the major somatostatin (SRIF) receptor subtype, the sst2A receptor, is localized at po

277 regarding traffic exposure and tumor hormone receptor subtype, the traffic-breast cancer association

278 Among the different existing receptor subtypes, the homomeric alpha7 nAChR has attrac

279 and desensitized states of AMPA and kainate receptor subtypes, the ion channels are closed, whereas

280 Of the five muscarinic receptor subtypes, the M5 receptor is the only one detec

281 Expression of 14 5-HT receptor subtypes, the serotonin transporter (SERT) and

282 contrasting signaling profiles, of adenosine receptor subtypes, these compounds might have therapeuti

283 minating between beta2- and beta3-containing receptor subtypes, Thio-THIP could be a valuable tool in

284 s show high affinity for all five muscarinic receptor subtypes, thus increasing the likelihood of unw

285 However, the contribution of GABAA receptor subtypes to anxiolysis is still controversial.

286 d examined the contributions of specific NPY receptor subtypes to these neural and behavioral effects

287 te in both sexes, but that distinct estrogen receptor subtypes underlie each aspect of potentiation i

288 e analyzed, and selectivity versus other P2X receptor subtypes was assessed.

289 The expression of EP receptor subtypes was determined by RT-PCR.

290 fibroblasts, which mainly expressed the S1P2 receptor subtype, we showed that FTY720-P selectively ac

291 ective pharmacological antagonists of opioid receptor subtypes, we reveal that endogenous mu-opioid r

292 ed cues, but the effects of blocking the two receptor subtypes were dissociable.

293 tro affinities of AMC20: toward dopaminergic receptor subtypes were measured in membrane homogenates

294 cacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with

295 ood since the same molecule can activate one receptor subtype while blocking another closely related

296 not clear whether targeting distinct GABA(A) receptor subtypes will have disproportionate benefits ov

297 that combined segments from NMDA and kainate receptors, subtypes with distinct pharmacological profil

298 ne acted as a potent agonist for all D2-like receptor subtypes, with the general rank order of potenc

299 the endogenous influence of specific opioid receptor subtypes within distinct brain regions remains

300 to 467-fold) toward MC4R over MC3R and MC5R receptor subtypes without compromising agonist potency.